Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAF1 | P04049 | 17/20 | 0.42 |
| ▸ | BRAF | P15056 | 15/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
| ▸ | KDR | P35968 | 1/20 | 0.40 |
| ▸ | JAK3 | P52333 | 1/20 | 0.40 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.40 |
| ▸ | GSK3A | P49840 | 1/20 | 0.40 |
| ▸ | GSK3B | P49841 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2114913 | 0.88 | CNR1 (0.51) | RAF1BRAFCNR1GSK3AGSK3B | |
| SCHEMBL2114247 | 0.87 | MAPT (0.52) | BRAF | |
| SCHEMBL2111921 | 0.86 | ABL1 (0.46) | RAF1BRAFCNR1LCKKDR | |
| SCHEMBL2115659 | 0.83 | BRAF (0.39) | RAF1BRAFCNR1 | |
| SCHEMBL2113285 | 0.82 | KMT2A (0.45) | RAF1BRAFCNR1 | |
| SCHEMBL2115180 | 0.82 | CNR1 (0.51) | RAF1BRAFCNR1GSK3B | |
| SCHEMBL2112593 | 0.81 | ABL1 (0.43) | RAF1BRAFCNR1GSK3AGSK3B | |
| SCHEMBL2114482 | 0.80 | NAMPT (0.44) | RAF1BRAFCNR1 | |
| SCHEMBL2111927 | 0.79 | L3MBTL1 (0.51) | — | |
| SCHEMBL2114034 | 0.78 | KCNQ3 (0.45) | CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | claimed |
| EP-2627637-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2013-08-21 | — | — | EP | claimed |
| WO-2012049190-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | WO | claimed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2627637-B1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2627637-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. Hoffmann-La Roche AG (CH) | 2013-08-21 | — | — | EP | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-8410107-B2 | N-pyridin-3-yl or N-pyrazin-2-yl carboxamides | HOFFMANN-LA ROCHE INC. (US) | 2013-04-02 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | US | disclosed |
| WO-2012049190-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094993-A1 | N-PYRIDIN-3-YL OR N-PYRAZIN-2-YL CARBOXAMIDES | APOB, CETP, NPC1L1 | RAF1 1876/4885BRAF 3160/4885CNR1 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.